Moving film about the anti-cancer with chemotherapy in advanced colorectal cancer clinical observation_0.doc

 PAGE \* MERGEFORMAT 11 Moving film about the anti-cancer with chemotherapy in advanced colorectal cancer clinical observation [Keywords:] anti-cancer anti-shift film, FOLFOX4 program, in advanced colorectal cancer Colorectal cancer is a common clinical gastrointestinal cancer, patients are still in the early surgical treatment, but recurrence and metastasis in patients with advanced inoperable systemic chemotherapy and traditional Chinese medicine is still the main treatment. Nearly 4 years, I moving pieces of anti-cancer chemotherapy with FOLFOX4 treatment of advanced colorectal cancer were clinical observations, are reported below. 1 Clinical data 1.1 Case inclusion criteria A clear pathological diagnosis of stage Ⅳ and locally advanced unresectable patients, the TNM stage Ⅲ, Ⅳ patients with primary colorectal cancer. Must have the patient himself or the witnesses to sign the written informed consent, age 18 ~ 75 years, pathology was adenocarcinoma, a tumor can be evaluated, within 3 months who did not receive chemotherapy, in general, may be, the card’s (Karnofsky) score [1]gt; 60 points, heart, liver and kidney function consistent with chemotherapy conditions and is expected survival greater than 3 months. 1.2 Exclusion criteria In 3 months who had received radiotherapy, chemotherapy and other special anti-cancer treatment, combined heart, liver, kidney or bone marrow dysfunction in severe damage, pregnant women and lactating women, those who do not meet the inclusion criteria. 1.3 General Information In January 2004 -2007 l2 months, were collected in our hospital comply with the standards of diagnosis and treatment of 70 patients with advanced colorectal cancer patients, aged 35 to 70 years old, average 50.2 years old. Random number table, randomly divided into treatment group (anti-cancer tablet combined with FOLFOX4 program shift) 36 patients in the control group (FOLFOX4 chemotherapy) 34 patients. the treatment group: male 16